We believe that EGFR promoter hypermethylation, after confirmation in larger data set, may represent a valuable and important asset to be considered in further studies investigating the role of EGFR as a therapeutic target in colorectal cancer patients. The gene discussed is EGFR; the disease is colorectal cancer.